Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

DexTech Medical

8.40 SEK

+11.26 %

Less than 1K followers

DEX

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+11.26 %
+19.15 %
-12.50 %
+1.20 %
+110.00 %
+90.91 %
+140.00 %
-83.87 %
-13.60 %

DexTech Medical operates in biotechnology. The company conducts research and development in the field of urological oncology, where common diseases include prostate cancer. A large part of the research is carried out in collaboration with other international players, research institutes and universities. The largest operations are found in the Nordic market. The company was founded in 2004 and is headquartered in Uppsala.

Read more
Market cap
155.28M SEK
Turnover
150.01K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2
2026

Interim report Q2'26

5.5
2026

Interim report Q3'26

31.8
2026

Annual report '26

All
Press releases
ShowingAll content types
Regulatory press releaseyesterday

DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3

DexTech Medical
Regulatory press release11/4/2025, 1:15 PM

DexTech Medical AB, Bulletin from the Annual General Meeting

DexTech Medical
Regulatory press release11/3/2025, 10:15 AM

DexTech Medical AB, Interim report July 1- September 30, 2025

DexTech Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release10/16/2025, 10:45 AM

DexTech Medical's Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3

DexTech Medical
Regulatory press release10/3/2025, 6:30 AM

DexTech Medical AB, Invitation to open Annual General Meeting and notice

DexTech Medical
Regulatory press release9/19/2025, 11:16 AM

Supplement, DexTech Medical AB: Annual Report 2024-07-01 - 2025-06-30

DexTech Medical
Regulatory press release9/19/2025, 10:30 AM

DexTech Medical AB, Annual Report 2024-07-01 - 2025-06-30

DexTech Medical
Regulatory press release8/29/2025, 1:15 PM

DexTech Medical AB, Year-end report 1 July 2024 - 30 June 2025

DexTech Medical
Regulatory press release8/20/2025, 9:40 AM

DexTech Medical's Myeloma Study, Dose Group 2

DexTech Medical
Regulatory press release5/19/2025, 9:20 AM

DexTech Medical's patent application regarding GMP manufacturing of OsteoDex is approved

DexTech Medical
Regulatory press release4/29/2025, 9:15 AM

DexTech Medical AB Interim report July 1, 2024 - March 31, 2025

DexTech Medical
Regulatory press release4/23/2025, 8:05 AM

DexTech Medical's myeloma study, strong follow-up results

DexTech Medical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.